Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Net Income (2016 - 2025)

Adma Biologics' Net Income history spans 13 years, with the latest figure at $49.4 million for Q4 2025.

  • For Q4 2025, Net Income fell 55.87% year-over-year to $49.4 million; the TTM value through Dec 2025 reached $146.9 million, down 25.67%, while the annual FY2025 figure was $146.9 million, 25.67% down from the prior year.
  • Net Income reached $49.4 million in Q4 2025 per ADMA's latest filing, up from $36.4 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $111.9 million in Q4 2024 to a low of -$18.8 million in Q2 2021.
  • Average Net Income over 5 years is $10.7 million, with a median of -$1.9 million recorded in 2023.
  • Peak YoY movement for Net Income: soared 1299.96% in 2024, then crashed 55.87% in 2025.
  • A 5-year view of Net Income shows it stood at -$16.5 million in 2021, then rose by 28.55% to -$11.8 million in 2022, then soared by 189.84% to $10.6 million in 2023, then surged by 956.22% to $111.9 million in 2024, then plummeted by 55.87% to $49.4 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Net Income are $49.4 million (Q4 2025), $36.4 million (Q3 2025), and $34.2 million (Q2 2025).